MEI Pharma Inc. (Nasdaq: MEIP) reported disappointing
data from a Phase II clinical study of Pracinostat to treat
myelodysplastic syndrome sending the stock price plunging $4.20 to $2.10.
Disappointing study data for MEI Pharma
March 23, 2015 at 14:31 PM EDT
